INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine): No. 3.43 (2012)Īutoimmune Polyglandular Syndrome (Care Report) Quality of Life in Patients with Diabetes Mellitus Type 2 with Metabolic Neuropathy against Pathogenic Therapy Organizational Problems During Administration of Insulin Preparations Under Current Public Funding 1 (2020)ĭynamics of Disability of Patients with Hypothyroidism in Vinnytsia Region in 2013–2015 INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine): Vol.

8 (2021)Įxperience of the department of reproductive endocrinology of Vinnytsia Regional Clinical Highly Specialized Endocrinology Center

Necrobiosis lipoidica: a rare clinical and pathomorphological case Forte on neuropathy symptoms was revealed. Long-term statistically significant positive effect of Nucleo C.M.P. Forte in the comprehensive treatment of patients with diabetes mellitus can prevent disorders that occur as a result of diabetic polyneuropathy. Forte had a statistically positive effect on the symptoms of neuropathy according to Neurological Symptom Score (7.27 ± 0.51 points, p < 0.001) and Total Symptom Score (6.53 ± 0.14 points, p < 0.001). Two-month administration of Nucleo C.M.P. The severity of neuropathy in first group before treatment was 10.23 ± 0.35 points, and after treatment - 7.62 ± 0.26 points, p 0.05) and Total Symptom Score (7.87 ± 0.38 points, p > 0.05) returned to the baseline or the changes were unreliable. Patients in both the first group and the second groups had a statistically positive effect on the symptoms after 10 days of in-patient treatment according to Neurological Symptom Score. In all patients before administration of the drug, after 10 days of in-hospital treatment and 2 months after treatment, clinical neurological examination was performed to evaluate neurological status, as well as dynamic examination using special clinical questionnaires (scales): Neurological Symptom Score and Total Symptom Score. Forte intramuscularly for 10 days while in hospital, then 1 capsule twice a day for 2 months. The second group (15 patients) before treatment received by group 1 was treated with Nucleo C.M.P. The first group (15 patients) received: alpha-lipoic acid at a dose of 600 mg intravenously, B vitamins: injections - for 10 days while in hospital and tablets - for one month at home. The level of glycated hemoglobin was from 7.1 to 10.4 %. Thirty patients with DM types 1 and 2 (8 men and 22 women) and DPN were examined. Forte in the comprehensive treatment of DPN. The objective was to study the effectiveness of Nucleo C.M.P. For adequate treatment of DPN, it is necessary to know that pathogenesis of neuropathy in DM is associated with overall metabolic lesion of neuronal membranes. Sometimes, DPN precedes the onset of clinical signs of DM. About 80 % of patients with DPN are asymptomatic, and the painful form of DPN is diagnosed in 10–20 % of cases. At the time of manifestation of DM, up to 6 % of patients have signs of diabetic polyneuropathy (DPN), after 5 years of the disease, they are observed in 15 %, and after 15 years - in 25 % of patients with DM. Forte Abstract Background.Diabetes mellitus (DM) is one of the socially significant diseases.

Vinnytsia Regional Clinical Highly-Specialized Endocrinology Center, Vinnytsia, Ukraineĭiabetes mellitus, diabetic polyneuropathy, Nucleo C.M.P. National Pirogov Memorial Medical University, Vinnytsia, Ukraine

Nucleo cmp forte capsules uses